Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Accounts Payables (2016 - 2025)

STRATA Skin Sciences' Accounts Payables history spans 15 years, with the latest figure at $2.8 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 13.36% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 13.36% increase, with the full-year FY2025 number at $2.8 million, up 13.36% from a year prior.
  • Accounts Payables hit $2.8 million in Q4 2025 for STRATA Skin Sciences, down from $3.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for SSKN hit a ceiling of $4.4 million in Q3 2022 and a floor of $1.7 million in Q3 2024.
  • Historically, Accounts Payables has averaged $3.1 million across 5 years, with a median of $3.0 million in 2023.
  • Biggest five-year swings in Accounts Payables: soared 76.17% in 2022 and later tumbled 44.6% in 2024.
  • Tracing SSKN's Accounts Payables over 5 years: stood at $2.8 million in 2021, then increased by 21.37% to $3.4 million in 2022, then fell by 2.39% to $3.3 million in 2023, then decreased by 27.22% to $2.4 million in 2024, then increased by 13.36% to $2.8 million in 2025.
  • Business Quant data shows Accounts Payables for SSKN at $2.8 million in Q4 2025, $3.0 million in Q3 2025, and $2.9 million in Q2 2025.